South Carolina § 44-6-1030 Recommendation of therapeutic classes of drugs to be included on preferred drug list.

South Carolina Statutes

§ 44-6-1030 — Recommendation of therapeutic classes of drugs to be included on preferred drug list.

South Carolina § 44-6-1030

Title 44HEALTH

Ch. 6DEPARTMENT OF HEALTH AND HUMAN SERVICES

This text of South Carolina § 44-6-1030 (Recommendation of therapeutic classes of drugs to be included on preferred drug list.) is published on Counsel Stack Legal Research, covering South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

S.C. Code Ann. § 44-6-1030 (2026).

Text

The committee must recommend to the department therapeutic classes of drugs that should be included on a preferred drug list. For those recommended classes, the committee shall recommend the drug or drugs considered preferred within that class based on safety and efficacy. In determining safety and efficacy, the committee may consider all submitted public comment or clinical information including, but not limited to, scientific evidence, standards of practice, peer-reviewed medical literature, randomized clinical trials, pharmacoeconomic studies, and outcomes research data. The committee also shall recommend prior authorization criteria for nonpreferred drugs in the recommended therapeutic classes.

Free access — add to your briefcase to read the full text and ask questions with AI

The committee must recommend to the department therapeutic classes of drugs that should be included on a preferred drug list. For those recommended classes, the committee shall recommend the drug or drugs considered preferred within that class based on safety and efficacy. In determining safety and efficacy, the committee may consider all submitted public comment or clinical information including, but not limited to, scientific evidence, standards of practice, peer-reviewed medical literature, randomized clinical trials, pharmacoeconomic studies, and outcomes research data. The committee also shall recommend prior authorization criteria for nonpreferred drugs in the recommended therapeutic classes.